> Lilly closing two animal health manufacturing plants picked up from Novatis. > BioClinica notches up another deal, this time with EPS.
> Icon launches new tech with promise to simplify adaptive trials. > Parexel dims its revenue expectations despite a solid quarter. > In the midst of cuts, Parexel signs new research deal. marketing firm to help it reach more patients. > Big investor pushes 'underperforming' J&J to step up or split up. > State AG's protest against Gilead pricing destined to fail, legal observers suggest. Article | Follow Riding Q4 diabetes growth, Lilly aims for even more with Jardiance. cost watchdog nixes pricey biologics for moderate rheumatoid arthritis. FiercePharmaManufacturing article | Follow ICYMI: U.K. FiercePharmaAsia article | Follow Novartis is revamping its manufacturing after having disposed of 25 plants. Pharma No obvious China baby bump for J&J as one-child policy ends. > Venetoclax grabs third FDA 'breakthrough' for blood cancer. > The top 10 (possible) blockbusters that (might) launch this year. FierceBiotechResearch article | Follow Turn out the lights, the party is over: Gov't finds Theranos lab poses 'immediate jeopardy to patient safety.' CNBC article | Follow Neos wins FDA approval for a melts-in-your-mouth take on Adderall for ADHD. Moreīiotech UT Southwestern team IDs next-gen approach to fighting pancreatic cancer. > Admetsys and Hospira have partnered on an artificial pancreas the Admetsys device will use injectable dextrose from Hospira to enable more precise glucose control to protect from hypoglycemic episodes during hospitalization. The device works via an existing peripheral IV catheter. > The FDA has cleared a modified version of the needle-free blood draw for hospital patients that it had already approved. FierceAnimalHealth story | Follow Edwards Lifesciences ($EW) has granted almost a half a million dollars to medical device incubator the Fogarty Institute for Innovation toward the financing of new med tech startups. with two more confirmed cases in Washington state. Article | Follow ICYMI yesterday: Sony, Carlyle Group, KKR among bidders for Toshiba's imaging unit, expected to fetch $3B+. Israeli VC backed by Philips and Teva looking to invest $26M in promising med tech startups. The web-based test takes 5 minutes and utilizes eye-tracking technology to assess recognition memory and hippocampal impairment. In addition, the company reported $6.5 million in new funding, led by Khosla Ventures and supported by Social Capital, Founders Fund, AME Cloud Ventures and iSeed Ventures. The goal is to advance research and treatment of cognitive diseases like Alzheimer's.
Palo Alto, CA's Neurotrack launched its first product, the Imprint, a digital cognitive assessment test for the evaluation of patients who may be at risk for cognitive decline.
0 kommentar(er)
